Schering AG Bolsters MS Pipeline With Acquisition Of Celera Research Program
This article was originally published in The Pink Sheet Daily
Executive Summary
Celera’s cathepsin S inhibitor program includes CRA-028129, now in Phase I, for treatment of autoimmune diseases.
You may also be interested in...
Bayer Has Schering AG Green Light
Bayer has met the quota for percentage of shares needed to acquire Schering AG, the firm said June 19
Tarceva Pancreatic Cancer Indication Turned Down In The EU
Roche will consider requesting a re-examination of the negative decision by the Committee for Medicinal Products for Human Use.
Teva To Investigate High-Dose Copaxone
A Phase III trial will compare 40 mg/day glatiramer to the 20 mg/day approved dose.